ReviewReviews in endocrine & metabolic disorders2017
Updates in hyperkalemia: Outcomes and therapeutic strategies.
Review in Reviews in endocrine & metabolic disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.
- Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.European heart journal · 2018Pooled it
- Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study.ESC heart failure · 2020Trial
- Utility of inhaled β2-agonists in reducing serum potassium levels in adult patients with hyperkalemia: A scoping review.PloS one · 2026Article
- Biomarkers Linked to Malnutrition Identified According to GLIM Criteria Among Older Community-Dwelling Adults: Results from the ilSIRENTE Study.Nutrients · 2025Article
- Machine learning-based predictive tools and nomogram for in-hospital mortality in critically ill cancer patients: development and external validation using retrospective cohorts.BMC medical informatics and decision making · 2025Article
- The burden of hyperkalaemia in chronic kidney disease: a systematic literature review.Clinical kidney journal · 2025Article
- Hyperkalemia Is an Underestimated Risk Factor in COPD.International journal of chronic obstructive pulmonary disease · 2025Article
- Sodium Zirconium Cyclosilicate for Renin-Angiotensin-Aldosterone System Inhibitor Optimization in Patients with Heart Failure with Reduced Ejection Fraction: A Retrospective Analysis.Cardiology and therapy · 2024Article
- Watermelon-induced hyperkalemia in chronic kidney disease patients: perspective from Pakistan.Annals of medicine and surgery (2012) · 2024Article
- Epidemiology and risk factors for hyperkalaemia in heart failure.ESC heart failure · 2024Review
- The impact of hyperkalemia on ICU admission and mortality: a retrospective study of Chinese emergency department data.BMC emergency medicine · 2024Observational
- Lipid parameters, adipose tissue distribution and prognosis prediction in chronic kidney Disease patients.Lipids in health and disease · 2024Article
- Machine learning models for early prediction of potassium lowering effectiveness and adverse events in patients with hyperkalemia.Scientific reports · 2024Article
- At least one hyperkalemia episode is associated with mortality and disease progression in stage 3 CKD patients.Journal of nephrology · 2023Article
- Prediction of hyperkalemia in ESRD patients by identification of multiple leads and multiple features on ECG.Renal failure · 2023Article
- Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease.Clinical kidney journal · 2023Article
- Incidence rate of hypokalemic and its associated factors for patients undergoing noncardiac surgery: a retrospective analysis.Gland surgery · 2023Article
- Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.American journal of nephrology · 2023Article
- Machine Learning Models Predicting Cardiovascular and Renal Outcomes and Mortality in Patients with Hyperkalemia.Nutrients · 2022Article
- Novel Insights in the Physiopathology and Management of Obesity-Related Kidney Disease.Nutrients · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Hyperkalemia is a frequent clinical abnormality in patients with chronic kidney disease, and it is associated with higher risk of mortality and malignant arrhythmias. Severe hyperkalemia is a medical emergency, which requires immediate therapies, followed by interventions aimed at preventing its recurrence. Current treatment paradigms for chronic hyperkalemia management are focused on eliminating predisposing factors, such as high potassium intake in diets or supplements, and the use of medications known to raise potassium level. Among the latter, inhibitors of the renin-angiotensin aldosterone system are some of the most commonly involved medications, and their discontinuation is often the first step taken by clinicians to prevent the recurrence of hyperkalemia. While this strategy is usually successful, it also deprives patients of the recognized benefits of this class, such as their renoprotective effects. The development of novel potassium binders has ushered in a new era of hyperkalemia management, with a focus on chronic therapy while maintaining the use of beneficial, but hyperkalemia-inducing medications such as renin-angiotensin aldosterone system inhibitors. This review article examines the incidence and clinical consequences of hyperkalemia, and its various treatment options, with special emphasis on novel therapeutic agents and the potential benefits of their application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.